March 20, 2020 09:32 AM

TORRENT PHARMA share price has zoomed 6% and is presently trading at Rs 1,878.

Meanwhile, the BSE HEALTHCARE Index is at 11,925 (up 4.5%).

Among the top Gainers in the BSE HEALTHCARE Index today are TORRENT PHARMA (up 5.6%) and ASTRAZENECA PHARMA (up 5.4%).

ERIS LIFESCIENCES LIMITED (down 1.5%) and SHILPA MEDICARE (down 5.0%) are among the top losers today.

Over the last one year, TORRENT PHARMA has moved up from Rs 1,871 to Rs 1,878, registering a gain of Rs 7 (up 0.3%).

On the other hand, the BSE HEALTHCARE has moved down from 14,270 to 11,925, loss of 2,345 points (down 16.5%) during the last 12 months.

The top gainers among the BSE HEALTHCARE Index stocks during this same period were ABBOTT INDIA (up 86.7%), J.B.CHEMICALS (up 62.6%) and IPCA LABS (up 62.4%).

What About the Benchmark Indices?

The BSE Sensex is at 28,861 (up 1.7%).

The top gainers among the BSE Sensex stocks today are ONGC (up 5.5%), POWER GRID (up 5.5%) and BAJAJ AUTO (up 5.1%). Other gainers include HUL (up 5.1%) and ITC (up 5.0%). The most traded stocks in the BSE Sensex are SBI and ICICI BANK.

In the meantime, NSE Nifty is at 8,441 (up 0.3%). The top gainers in the NSE Nifty include GAIL (up 6.4%), POWER GRID (up 5.7%) and ONGC (up 4.8%). Other gainers include ITC (up 4.3%) and SUN PHARMA (up 4.2%) are among the top gainers in NSE Nifty.

Over the last 12 months, the BSE Sensex has moved down from 38,363 to 28,861, registering a loss of 9,502 points (down 25.04%).

TORRENT PHARMA Financial Update...

TORRENT PHARMA net profit stood at Rs 3 billion for the quarter ended December 2019, compared to a profit of Rs 2 billion a year ago. Net Sales declined 4.1% to Rs 19.7 billion during the period as against Rs 20.5 billion in October-December 2018.

For the year ended March 2019, TORRENT PHARMA reported 17.0% increase in net profit to Rs 7.9 billion compared to net profit of Rs 6.8 billion during FY18.

Revenue of the company grew 29.0% to Rs 77 billion during FY19.

The current Price to earnings ratio of TORRENT PHARMA, based on rolling 12 month earnings, stands at 56.5x.